The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

(2012) E. Caproni et al.   JOURNAL OF IMMUNOLOGY

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer

(2012) Nikunj M. Shukla et al.   PLoS One

Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine

(2012) William C. Weldon et al.   PLoS One

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

(2012) Joanne M. Lumsden et al.   VACCINE

Toward self-adjuvanting subunit vaccines: Model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines

(2011) Nikunj M. Shukla et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28

(2011) J. S. Pufnock et al.   BLOOD

Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

(2011) M. A. Morse et al.   CLINICAL CANCER RESEARCH

TLR-7 and -8 agonists as vaccine adjuvants

(2011) Mark A Tomai et al.   Expert Review of Vaccines

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets

(2011) Kathrin Kastenmüller et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma

(2011) Rupa Narayan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Programming the magnitude and persistence of antibody responses with innate immunity

(2011) Sudhir Pai Kasturi et al.   NATURE

The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848

(2011) Kai Zhao et al.   VACCINE

A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

(2011) Chunmei Cheng et al.   VACCINE

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

(2011) Dmitri Smirnov et al.   VACCINE

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells

(2010) G. Schreibelt et al.   BLOOD

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

(2010) D. Rajagopal et al.   BLOOD

An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles

(2010) L. S. Velasquez et al.   Clinical and Vaccine Immunology

Combination adjuvants: the next generation of adjuvants?

(2010) George Mutwiri et al.   Expert Review of Vaccines

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice

(2010) Gul Ahmad et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Characterization of human DNGR-1+BDCA3+leukocytes as putative equivalents of mouse CD8α+dendritic cells

(2010) Lionel Franz Poulin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Capacity To Induce Cross-Presentation Dictates the Success of a TLR7 Agonist-Conjugate Vaccine for Eliciting Cellular Immunity

(2010) J. Z. Oh et al.   JOURNAL OF IMMUNOLOGY

TLR ligands induce synergistic interferon-β and interferon-λ1 gene expression in human monocyte-derived dendritic cells

(2010) Sanna M. Mäkelä et al.   MOLECULAR IMMUNOLOGY

TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity

(2010) Jun Du et al.   VACCINE

The antiviral activity of toll-like receptor 7 and 7/8 agonists

(2009) R.L. Miller et al.   DRUG NEWS & PERSPECTIVES

Topical resiquimod promotes priming of CTL to parenteral antigens

(2009) Brent A. Chang et al.   VACCINE

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

(2009) Susan L. Baldwin et al.   VACCINE

Recognition of viral single-stranded RNA by Toll-like receptors☆

(2008) S DIEBOLD   ADVANCED DRUG DELIVERY REVIEWS

Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity against Leishmania major in BALB/c Mice

(2008) W.-W. Zhang et al.   INFECTION AND IMMUNITY

Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-  (IFN- )

(2008) M. Lehner et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates

(2008) Chutitorn Ketloy et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY